EPHA2mutation was present in LUSC, and it could increase tumor invasion and survival by activating thefocal adhesions and actin cytoskeletal regulatory proteins, indicating EPHA2 as apotential therapeutic target of LUSC (Faoro et al.,2010), which was consistent with our findings. Here, EPHA2 is linked to neoplasm.